-
Recent Posts
- December 01 2013 – Human stem cells converted to functional lung cells
- November 30 2013 – Keyhole lung transplant performed on 60-year-old in Chennai
- November 27 2013 – FibroGen Announces Observations of Possible Disease Stabilization and Improvement in Interim Analysis of Phase 2 Study of FG-3019
- November 15 2013 – Enzo Biochem Announces Study in Leading Scientific Journal Linking Idiopathic Pulmonary Fibrosis, a Deadly Human Disease with No Effective Treatment Options, to Presence of a Monkey Virus
- November 10 2013 – Research by Saint Louis University scientists offers way to disrupt fibrosis
Recent Comments
- Fish With Captain Frank on June 20 2012 MicroDose Therapeutx and Moerae Matrix Announce Collaboration to Develop Novel Inhaled Treatment for Idiopathic Pulmonary Fibrosis (IPF)
- Raymond on June 9 2011 – Ascend Trial – Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- Johng182 on InterMune to Provide Overview of Corporate Strategy, Update on Esbriet Commercialization Plans in the EU and Details of Phase 3 ASCEND Study
- Johnf73 on InterMune to Provide Overview of Corporate Strategy, Update on Esbriet Commercialization Plans in the EU and Details of Phase 3 ASCEND Study
- extreme rush on June 28 2012 Grasping at Straws while Gasping for Air
Archives
Categories
Meta
Monthly Archives: May 2011
InterMune to Provide Overview of Corporate Strategy, Update on Esbriet Commercialization Plans in the EU and Details of Phase 3 ASCEND Study
BRISBANE, Calif., May 25, 2011 /PRNewswire/ — InterMune (NASDAQ:ITMN – News) will outline the company’s corporate strategy and vision for 2015, including an update on its ongoing plans to commercialize Esbriet® (pirfenidone) in Europe, as well as details on ASCEND, … Continue reading
Posted in Uncategorized
2 Comments
May 16 2011 Promedior Presents Clinical Data for PRM-151 (rhPTX-2) in Idiopathic Pulmonary Fibrosis at American Thoracic Society 2011 – Data Highlights Safety and Biomarker Activity in Patients with IPF
MALVERN, PA – May 16, 2011 – Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic and inflammatory diseases, presented data from a clinical study of PRM-151 (recombinant human Pentraxin-2 (PTX-2)) at the 2011 American Thoracic … Continue reading
Posted in Uncategorized
Leave a comment
May 16 2011 InterMune Announces Presentation of Positive Pirfenidone Data at the International Conference of the American Thoracic Society (ATS) – New ASCEND trial
BRISBANE, Calif., May 16, 2011 /PRNewswire via COMTEX/ — InterMune, Inc. (Nasdaq: ITMN) today announced that an oral presentation and a poster presentation related to the company’s development program for pirfenidone in idiopathic pulmonary fibrosis (IPF) will be presented at … Continue reading
Posted in Uncategorized
Leave a comment
May 13 2011 Pirfenidone Phase 3 Results Published Today in The Lancet
BRISBANE, Calif., May 13, 2011 /PRNewswire/ — InterMune, Inc. (Nasdaq: ITMN) today announced the publication of results from two Phase 3 trials demonstrating that treatment with pirfenidone, a novel antifibrotic and anti-inflammatory drug, was associated with favorable effects on lung … Continue reading
Posted in Uncategorized
1 Comment
May 12, 2011 Evidence for Human Lung Stem Cells
Results Human lungs contain undifferentiated human lung stem cells nested in niches in the distal airways. These cells are self-renewing, clonogenic, and multipotent in vitro. After injection into damaged mouse lung in vivo, human lung stem cells form human bronchioles, … Continue reading
Posted in Uncategorized
2 Comments
May 5 2011 Promedior to Present Clinical Data for PRM-151 (rhPTX-2) in Idiopathic Pulmonary Fibrosis at ATS 2011
May 5 2011 Promedior to Present Clinical Data for PRM-151 (rhPTX-2) in Idiopathic Pulmonary Fibrosis at ATS 2011 MALVERN, Pa.–(BUSINESS WIRE)– Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic and inflammatory diseases, today announced that … Continue reading
Posted in Uncategorized
Leave a comment